KLRC2 and diffuse large B-cell lymphoma: As shown in Figure 3, multivariate analysis including gender (male vs. female), IPI (0–3 vs. 4–5), lymphoma subtype (diffuse large B-cell lymphoma (DLBCL) vs. other), B symptoms (A vs. B), iPET status (favorable iPET vs. unfavorable iPET) and NKG2C−/− status (NKG2C−/− vs. NKG2C+/− or NKG2C+/+) showed that besides B symptoms (p = 0.013; HR:2.51; 95% CI: 1.218 to 5.173) and iPET (p = 0.001; HR: 4.242; 95% CI: 1.781 to 10.102), the NKG2C−/− status was an independent predictive factor for 2-year PFS in B-NHL patients (p = 0.005; HR: 4.758; 95% CI: 1.617 to 13.999; n = 379).